Free Trial

Enovis Q1 2023 Earnings Report

Enovis logo
$43.12 +0.63 (+1.48%)
(As of 12/20/2024 05:31 PM ET)

Enovis EPS Results

Actual EPS
$0.44
Consensus EPS
$0.37
Beat/Miss
Beat by +$0.07
One Year Ago EPS
$0.37

Enovis Revenue Results

Actual Revenue
$406.20 million
Expected Revenue
$389.95 million
Beat/Miss
Beat by +$16.25 million
YoY Revenue Growth
+8.20%

Enovis Announcement Details

Quarter
Q1 2023
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Slide Deck

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Enovis Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Enovis Corporation: Reasonably Valued With Caveats
Enovis to Participate in Upcoming Investor Conferences
Enovis: Strong Market Position and Growth Potential Justify Buy Rating
See More Enovis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enovis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enovis and other key companies, straight to your email.

About Enovis

Enovis (NYSE:ENOV) operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

View Enovis Profile

More Earnings Resources from MarketBeat

Upcoming Earnings